Clinical Trial Update: Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating toripalimab in combination with gemcitabine for recurrent or metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN